Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGEN), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. (NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. This news page highlights company announcements, clinical updates and capital markets developments that relate to NervGen’s progress.
Readers can find coverage of NervGen’s listing and trading on Nasdaq under the symbol NGEN, along with commentary from the company on how this listing fits into its evolution as a biopharmaceutical issuer. News items also describe the company’s clinical milestones, including data from the Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291 in individuals with chronic spinal cord injury.
The company reports that NVG-291, a subcutaneously administered neuroreparative peptide, has demonstrated durable improvements in function, independence and quality of life in chronic SCI, supported by changes in corticospinal and reticulospinal signaling. Updates on regulatory interactions, such as FDA Type C and planned End-of-Phase 2 meetings, are also reflected in NervGen’s news flow, as the company works to define the development and registration pathway for NVG-291.
Because NervGen focuses on conditions with significant unmet medical need, its news often centers on clinical trial data, regulatory designations such as FDA Fast Track and EMA Orphan Drug status for NVG-291 in spinal cord injury, and strategic steps toward late-stage development. Investors and observers can use this page to follow how NervGen describes its progress in advancing NVG-291 and its next-generation candidate NVG-300 within the broader context of neurotrauma and neurologic disease research.
NervGen (NASDAQ: NGEN) announced a voluntary delisting from the TSX Venture Exchange, effective at market close on March 16, 2026. The company will continue trading on Nasdaq under NGEN and no shareholder action is required.
The move aims to eliminate duplicate exchange fees, reduce legal/accounting and regulatory complexity, and let management focus on late-stage development of NVG-291. NervGen will remain a reporting issuer across Canadian provinces. The company also terminated its ATM program; from Jan 1–Mar 12, 2026 it issued 245 shares at a weighted average price of $6.20, for aggregate net proceeds of $1,489.
NervGen (TSXV:NGEN, NASDAQ:NGEN) on March 4, 2026 appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs. Both hires bring 30+ years of experience to support advancement of NVG-291 toward potential approval and to center patient voices in clinical strategy.
NervGen (NASDAQ:NGEN) announced executive participation at multiple investor conferences in late Feb–March 2026, including virtual and in-person presentations and 1x1 investor meetings.
Presentations: Oppenheimer (Feb 25, virtual, 12:40–1:10 PM ET), TD Cowen (Mar 2, Boston, 2:30–3:00 PM ET) and Leerink (Mar 8–11, Miami, 1x1 meetings). A live webcast and archived replay will be available on the company investor website.
NervGen (TSXV:NGEN, NASDAQ:NGEN) announced that Chief Financial Officer Bill Adams will retire effective March 15, 2026. The company has engaged an executive search firm to find a successor, and Mr. Adams will remain in an advisory capacity to support the transition.
The release notes Mr. Adams served six years and highlights NervGen's progression to a Nasdaq-listed company advancing NVG-291 into late-stage development.
NervGen (NASDAQ:NGEN) will present clinical data from the Phase 1b/2a CONNECT SCI study at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium in Washington, DC, Feb 15–17, 2026.
Adam Rogers, MD, CEO, will present on Sunday, Feb 15, 2026, 4:15–5:00 pm ET, in a session titled "Emerging Therapies with Challenges and Opportunities for the Future," discussing durable functional, independence, and quality-of-life improvements observed in chronic spinal cord injury.
NervGen (TSXV:NGEN; NASDAQ:NGEN) appointed Adam Rogers, MD, as President and Chief Executive Officer effective February 9, 2026. The Board cited his interim leadership, including the Company’s recent Nasdaq listing, and his physician-executive experience advancing NVG-291 toward late-stage development.
The company granted 717,891 stock options with a four-year vesting schedule and specified exercise prices and terms.
NervGen (NASDAQ:NGEN) will ring the Nasdaq closing bell on January 22, 2026 in New York City to mark its recent Nasdaq listing. Adam Rogers, MD, Chairman and Interim CEO, will be joined by management, board members, advisors and guests. The ceremony broadcast begins at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower and available on Nasdaq’s X and Facebook pages. The event highlights NervGen’s focus on developing neuroreparative therapeutics for spinal cord injury.
NervGen Pharma (NASDAQ:NGEN) announced its common shares began trading on Nasdaq on January 8, 2026. The company is a clinical-stage biopharmaceutical developer of neuroreparative therapeutics, advancing NVG-291 for spinal cord injury (SCI).
Recent expanded Phase 1b/2a CONNECT SCI data (announced Nov 24, 2025) showed statistically significant improvements in upper-limb corticospinal signaling and reductions in hyperactive reticulospinal signaling, with reported durable functional and quality-of-life gains in chronic SCI. NervGen plans an FDA End-of-Phase 2 meeting in early 2026 to align on development and registration pathways.